Athyrium Capital Management specializes in global healthcare sector investments, advising funds with over $1 billion in committed capital. The firm invests in a wide range of financial instruments, including royalties, structured credit, equities, and select special situations. Athyrium typically participates in post-IPO debt, private equity, and post-IPO equity rounds, with investments ranging from $22.5 million to $325 million.
Notable portfolio companies include BioCryst Pharmaceuticals, Clover Health, Halozyme Therapeutics, and VillageMD. Athyrium's investment strategy focuses on structured investments in the healthcare sector, providing capital solutions tailored to each company's specific needs. The firm's expertise in healthcare and financial structuring allows it to offer value-added support to its portfolio companies beyond capital investment.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.